Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic (Nasdaq: HOLX) has unveiled its first national direct-to-consumer advertising campaign, launching during the 'Big Game' on NBC on February 13, 2022. The campaign, titled "Her Health is Her Wealth", features Mary J. Blige and aims to promote preventive screenings for women, emphasizing the importance of regular health check-ups that many missed during the COVID-19 pandemic. Research indicates that nearly 50% of women aged 16-54 have not had a health screening in the past year. The campaign will also include digital activations via ScreeningsForHer.com.
Hologic, Inc. (NASDAQ: HOLX) reported preliminary revenue of
Hologic, Inc. (NASDAQ: HOLX) will release its financial results for Q1 Fiscal 2022 on February 2, 2022, after market close. Management will host a conference call at 4:30 p.m. ET the same day. Interested participants can join by dialing specified numbers or via a live webcast on the company's website. A replay will be available until February 25, 2022. Hologic is dedicated to enhancing women's health through innovative medical technology solutions.
Hologic, Inc. (NASDAQ: HOLX) has expanded its Global Access Initiative (GAI) to include the Aptima® SARS-CoV-2 assay, aimed at improving access to COVID-19 diagnostics in resource-limited countries. The GAI, launched in 2018, facilitates affordable diagnostic testing without upfront costs. Hologic has already provided over 700,000 SARS-CoV-2 tests during the pandemic, partnered with organizations like WHO and UNICEF. This expansion enhances accessibility and reflects Hologic's commitment to equitable health systems worldwide.
Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 p.m. Eastern Time. The presentation and Q&A session will be webcast live and accessible through Hologic’s investor website. The webcast will remain available for 30 days post-event. Hologic focuses on enhancing women's health through early detection and treatment technologies. For further details, visit www.hologic.com.
Hologic (NASDAQ: HOLX) has completed necessary regulatory filings for its new automation solution, Panther Trax, which will enhance testing capabilities in laboratories. This product is now recognized as a Class I medical device by the FDA and CE-marked in Europe, with plans for availability in Canada, Australia, and New Zealand. The Panther system supports various molecular tests, including for COVID-19, and aims to assist labs in managing increased testing demands effectively. Its scalable solutions will enable labs to optimize space and cost-efficiency while expanding testing volume.
Hologic, Inc. (NASDAQ: HOLX) announced data showcasing the Breast Cancer Index™ (BCI) as a key tool predicting treatment benefits in hormone receptor-positive (HR+) breast cancer patients. Presented at the 2021 San Antonio Breast Cancer Symposium, findings reveal that BCI predicts recurrence-prevention advantages from extended endocrine therapy (EET) and highlights biomarkers critical for assessing treatment effectiveness. The research emphasizes patient compliance and informed decisions, confirming significant net treatment benefits while considering adverse effects. BCI is unique in guiding individualized treatment decisions.
Hologic, Inc. (NASDAQ: HOLX) has finalized its acquisition of Bolder Surgical, enhancing its laparoscopic device portfolio aimed at women's health. This strategic move integrates Bolder's advanced energy vessel sealing technologies, including the CoolSeal® Vessel Sealing Suite, into Hologic's offerings. The acquisition is expected to provide better surgical options for OB/GYN specialists and broaden Hologic's market presence in minimally invasive treatments.
Hologic, Inc. (Nasdaq: HOLX) announced that its SARS-CoV-2 tests successfully detect the new Omicron variant. The tests, including the Aptima SARS-CoV-2 Assay, were verified through genetic sequencing of over 175 samples. Hologic's assays are stated to be unaffected by the variant's mutations. With over 130 million SARS-CoV-2 tests distributed, the company has significantly impacted global testing. The automated Panther systems can process over 1,000 tests daily.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
